Adaptive Biotechnologies Corporation Common Stock ADPT

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

• The Motley Fool 12 jul

  An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

  Harlan Robins, chief scientific officer of Adaptive Biotechnologies, sold 386,240 shares worth $8.5 million on July 2, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in March. Despite the sale, Robins retained over 1 million shares valued at $21.6 million. The transaction appears to be a diversification move rather than a sign of concern, as the company's MRD diagnostics business is accelerating with 35% revenue growth and narrowing losses.

  

• Benzinga 17 jun

  Adaptive Biotechnologies Business Separation May Unlock Greater Value

  Adaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. William Blair analyst Andrew Brackmann believes the separation could simplify the investment story and create strategic flexibility for the MRD franchise. The Immune Medicine segment is expected to contribute little to valuation and carries $15-20 million in annual cash burn. The company also priced a $300 million convertible senior notes offering to repay debt and fund MRD initiatives.

  

• GlobeNewswire Inc. 17 jun

  Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

  Adaptive Biotechnologies priced a $300 million offering of 0% convertible senior notes due 2031 (expandable to $345 million with greenshoe option). The company plans to use proceeds to repay its OrbiMed Purchase Agreement, fund capped call transactions at a 100% premium, repurchase $25 million in common stock, and support general corporate purposes and MRD business initiatives. The notes have an initial conversion price of $24.11 per share, representing a 40% premium to the June 16, 2026 closing price of $17.22.

  

• Benzinga 16 jun

  Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

  Adaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to unlock shareholder value. The MRD segment has shown strong growth, increasing revenue from $103 million in 2023 to $212 million in 2025, while the Immune Medicine segment has advanced in drug discovery capabilities. The company expects to finalize its separation strategy by end of 2026. ADPT shares rose 0.74% to $17.59, with analysts maintaining a Buy rating and average price target of $20.20.

  

• Benzinga 16 jun

  Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED)

  U.S. stock futures showed mixed performance on Tuesday following a preliminary U.S.-Iran agreement. The Dow Jones and Nasdaq 100 advanced while the S&P 500 fell slightly. Key movers included SpaceX surging with a market cap nearing $3 trillion, Dave and Buster's dropping 11.44% on weak earnings, Western Digital gaining 4.97% on analyst upgrade, and Paranovus Entertainment surging 30.07% on a direct offering announcement.